Abstract: The present disclosure relates to novel compounds for use in therapeutic treatment of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to processes and intermediates for the preparation of such compounds, methods of using such compounds and pharmaceutical compositions comprising the compounds described herein.

Abstract: An electrode assembly that is adjustable in size, as well as systems, and methods of use thereof are described. The electrode assembly includes multiple electrode portions including at least a first electrode portion and a second electrode portion, the second electrode portion disposed on the first electrode portion at an edge of the first electrode portion, wherein the second electrode portion has a cutout, and wherein the first electrode portion spans the cutout. The electrode assembly is configured to be used with a medical device, such as an external defibrillator. A process of automatically selecting a usage mode of a medical device based on detecting which electrode portion(s) has been removed from an electrode storage tray is also described.

Abstract: A golf club head has a body having a ball striking face, a rear opposite the ball striking face, a crown, a sole, a heel, and a toe, the body having a void defined by a peripheral edge on the sole. The body further defines a cover that extends over the void and forms at least a portion of the crown. At least a portion of the peripheral edge of the void includes a lip extending from the peripheral edge inwardly into the void. The golf club head may additionally or alternately include one or more weight receptacles connected to the sole and having an opening in the sole, such that each weight receptacle is configured to receive insertion of a weight through the opening.

Abstract: A compound of Formula (I): pharmaceutically acceptable salts thereof, deuterated analogs thereof, compositions thereof, and methods of treating disease using a compound thereof are disclosed.

Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.

Abstract: A high availability aircraft network architecture incorporating smart points of presence (SPoP) is disclosed. In embodiments, the network architecture divides the aircraft into districts, or physical subdivisions. Each district includes one or more mission systems (MS) smart network access point (SNAP) devices for connecting MS components and devices located within its district to the MS network. Similarly, each district includes one or more air vehicle systems (AVS) SNAP devices for connecting AVS components and devices within the district to the AVS network. The AVS network may remain in a star or hub-and-spoke topology, while the MS network may be configured in a ring or mesh topology. Selected MS and AVS SNAP devices may be connected to each other via guarded network bridges to securely interconnect the MS and AVS networks.

Abstract: An apparatus for a bone fusion assembly is provided for compressing adjacent bones across a bone fusion site to encourage fusion thereof. The bone fusion assembly includes a generally elongate member comprising a plate that has one or more fixation apertures to receive fasteners that are configured to be coupled with the adjacent bones. A threaded fastener comprising a bone screw, including a head portion and a shank, is configured to traverse the bone fusion site. A slanted aperture disposed in the plate is configured to receive the bone screw at a predetermined angle with respect to a plane of the plate. The slanted aperture comprises a smooth countersunk surface and one or more teeth that are configured to cooperate with the head portion of the bone screw to compress the adjacent bones together and encourage bone fusion therebetween.

Abstract: Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, X, W, Y1, Y2, Z1, and Z4 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Abstract: The present disclosure relates to novel compounds for use in therapeutic treatment of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to processes and intermediates for the preparation of such compounds, methods of using such compounds and pharmaceutical compositions comprising the compounds described herein.

Abstract: The present disclosure relates generally to methods of using modulators of COT (cancer Osaka thyroid) for treating, stabilizing, or lessening the severity or progression of liver disease, in particular, Nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH).

Abstract: The present disclosure relates generally to modulators of Cot (cancer Osaka thyroid) and methods of use and manufacture thereof.

Abstract: Provided herein are compounds of Formula (I): the formula(I): wherein the various substituents are defined herein,

Abstract: A compound of Formula (I): pharmaceutically acceptable salts thereof, deuterated analogs thereof, compositions thereof, and methods of treating disease using a compound thereof, wherein the variable substituents are disclosed herein.

Abstract: A compound of Formula (I): pharmaceutically acceptable salts thereof, deuterated analogs thereof, compositions thereof, and methods of treating disease using a compound thereof are disclosed.

Abstract: Provided herein are compounds and methods for the treatment or prevention of Zika virus infection. For example, a compound of the formula(I): Wherein the variable substituents are described herein.

Abstract: An apparatus and method are provided for a syndesmosis treatment construct configured to be placed into a cinched configuration that presses a first bone against a second bone. The syndesmosis treatment construct comprises a proximal fixator to contact the first bone and a distal fixator to contact the second bone. A first suture and a second suture are parallelly looped through the distal fixator. A free splice slidably rides on proximal ends and distal ends of both of the first and second sutures. The distal ends are looped through the proximal fixator and bound within a stitch splice. The proximal ends are passed outside of the stitch splice and through the proximal fixator. The free splices compress and seize the proximal ends during pulling of the proximal ends by a practitioner so as to maintain the cinched configuration.

Abstract: A pipe connector includes a housing body defining an axial bore arranged to receive a pipe section having an end and extending between a housing top and a housing bottom. A sealing member is seated in the axial bore with a conical inner surface configured to interface with the end of the pipe section. A cap member with an opening is threadedly attachable to the housing top. A locking member is carried in the cap member and configured such that the pipe section is only movable through the locking member in a direction toward the sealing member. The locking member drives the pipe section downward along the conical inner surface and creates a fluid tight seal between the sealing member and the pipe section when the cap member is threaded down on the housing top with the end of pipe section engaging the conical inner surface of the sealing member.

Abstract: A smart network access point (SNAP) device is disclosed. In embodiments, the SNAP device includes trunk ports for accepting a network trunk cable (e.g., fiber optic trunk) and thereby connecting the SNAP device to an aircraft-based network of SNAP devices. The SNAP device includes switch ports for incorporating physical connections to mission systems (MS) or air vehicle systems (AVS) components and devices, providing a local smart point of presence (SPoP) throughout a physical subdivision (e.g., network district) of an aircraft. The SNAP device is configured for monitoring data exchanges between local MS/AVS components and the aircraft network. The SNAP device includes a cybersecurity module for connecting to local security components (e.g., data guards and multiple levels of security (MLS) encryption/decryption) or for providing built-in data guard and encryption/decryption services. The SNAP device includes power control components for managing power distribution to the connected local network components.

Abstract: A pipe connector includes a housing body arranged to receive a length of pipe including an end section having an enlarged diameter. A locking member split into two or more segments selectively connectable together around the length of pipe outside the housing body. The locking member is configured to lock the length of pipe within the housing body. At least one sealing member is positionable on the length of pipe between the end section and the locking member. At least one sealing member is compressible inside the housing body between the enlarged diameter of the end section of the locking member. A retaining member is positionable on the length of pipe and attachable to the housing body. The retaining member can secure the locking member to the housing body such that the locking member fills a gap outside the housing body between the length of pipe and the retaining member.

Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.